Prospective Trial of Mizoribine Versus Mycophenolate Mofetil in Cyclosporine-based Kidney Transplantation

LIU Bin,ZENG Fan-jun,MING Chang-sheng,LIN Zheng-bin,CHEN Zhi-shui,ZHANG Wei-jie,JIANG Ji-pin,WEI Lai
DOI: https://doi.org/10.3969/j.issn.1005-8982.2006.17.019
2006-01-01
Abstract:[Objective] To investigate the efficacy and safety of Mizoribine (MZR, bredinin) versus Mycophenolate mofetil (MMF) as maintainance agent in Cyclosporine (CsA)-based immunosuppressive regime in kidney transplantation. [Methods] Twenty-eight cadaveric kidney allograft recipients (male/female 19/9) were involved. The donor kidneys were harvested en bloc and flushed through WMO-1 solution. Warm ischemic time was 3~7 minutes, and cold ischemic time was 5~16 hours. These patients were divided into 2 groups: (1) CsA +MZR (n=14): the patients received MZR at a initial dose of 1~2 mg/(kg·d) in combination with CsA and Corcosteriod. CsA+MMF (n=14): patients received the triple-combined regime with CsA, MMF (1.5~2 g/d) and Corcosteriod as primary immunosuppressants. [Results] There was no loss of grafts or patients in each group at 6 months follow-up. No significant difference (P 0.05) with respect to the episodes of acute rejection (1/14 in MMF group vs. 1/14 in MZR group) and mean serum creatinine level [(98.6±2.5) μmol/L in MMF group vs. (100.2±1.7) μmol/L in MZR group] were observed. The incidence of gastrointestinal dysfunction and leukopenia were comparable. Nevertheless, 2 cases in MZR group underwent transient hyperglycemia probably due to high-dose Corcosteriod. [Conclusion] MZR is a potent immunosuppressant with lower hepatic toxicity. Instead of MMF, MZR could be used effectively as maintainable agent in Cyclosporine-based regime in kidney transplantation.
What problem does this paper attempt to address?